linaclotide · Linzess

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Irritable Bowel Syndrome with Constipation

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Chronic idiopathic constipation (CIC) in adults
  • Functional constipation (FC) in pediatric patients 2 years of age and older
Product first approved 2012Outside this platform's coverageFDA label
CN
  • Adult patients with IBS-C (Linzess, AstraZeneca partner)
Product first approved 2019astrazeneca.com
JP
  • Irritable bowel syndrome with constipation (IBS-C); chronic constipation added August 2018 (Linzess, Astellas)
Product first approved 2016americanpharmaceuticalreview.com
EU
  • Symptomatic treatment of moderate to severe IBS-C in adults (marketed in the EU as Constella)
Product first approved 2012EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Irritable Bowel Syndrome with Constipation
NCT04166058 · AbbVie
2019-11-19 – 2025-06-05 · Irritable Bowel Syndrome With Constipation, Functional Constipation
What this study did
NCT02316899 · Astellas Pharma Inc
2014-10-21 – 2016-03-29 · Irritable Bowel Syndrome With Constipation (IBS-C)
What this study did
NCT00765999 · Forest Laboratories
2008-10-31 – 2012-01-31 · Chronic Constipation, Irritable Bowel Syndrome With Constipation
What this study did
Other / comorbidity
NCT05652205 · AbbVie
2022-12-29 – 2025-09-02 · Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
What this study did
NCT02809105 · Astellas Pharma Inc
2016-06-24 – 2017-11-10 · Chronic Constipation
What this study did
NCT02291679 · Ironwood Pharmaceuticals, Inc.
2014-10 – 2015-08 · Chronic Idiopathic Constipation
What this study did
NCT01642914 · Forest Laboratories
2012-08 – 2013-08 · Chronic Constipation, Constipation
What this study did
NCT00730015 · Ironwood Pharmaceuticals, Inc.
2008-08 – 2009-10 · Chronic Constipation
What this study did
NCT00765882 · Forest Laboratories
2008-09 – 2009-08 · Chronic Constipation
What this study did
Phase 2 (10)
Irritable Bowel Syndrome with Constipation
NCT02559817 · Forest Laboratories
2015-11-01 – 2019-08-30 · Irritable Bowel Syndrome With Constipation
What this study did
NCT02559206 · Ironwood Pharmaceuticals, Inc.
2015-10-22 – 2016-09-30 · Irritable Bowel Syndrome With Constipation
What this study did
NCT01714843 · Astellas Pharma Inc
2012-08-10 – 2013-12-07 · Constipation-predominant Irritable Bowel Syndrome (IBS-C)
What this study did
NCT00460811 · Ironwood Pharmaceuticals, Inc.
2007-04 – 2008-04 · Irritable Bowel Syndrome With Constipation
What this study did
Other / comorbidity
NCT03796884 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2019-10-30 – 2027-01 · Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
What this study did
NCT04110145 · Allergan
2019-10-14 – 2021-04-20 · Functional Constipation
What this study did
NCT02559570 · Forest Laboratories
2015-11-03 – 2018-05-29 · Functional Constipation in Children Ages 6-17 Years
What this study did
NCT00402337 · Ironwood Pharmaceuticals, Inc.
2006-11 – 2008-02 · Chronic Constipation
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06692673 · University of Florida
2025-12-01 – 2026-04-07 · Patients Scheduled for Colonoscopy
What this study did
Phase 1 (4)
Other / comorbidity
NCT07569419 · University of Nottingham
2026-03-09 – 2026-10 · Cystic Fibrosis (CF)
What this study did
NCT05107219 · University of Wisconsin, Madison
2022-11-30 – 2026-02-06 · Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
What this study did
NCT02220348 · Forest Laboratories
2014-07-31 – 2019-05-31 · Breast Feeding, Constipation, Irritable Bowel Syndrome
What this study did
NCT01950403 · Mayo Clinic
2013-09 – 2018-02-22 · Colorectal Cancer, Healthy, no Evidence of Disease
What this study did
Phase 4 (8)
Irritable Bowel Syndrome with Constipation
NCT07431957 · Md Mehedi Shahriar
2026-02-20 – 2027-01-31 · Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C), Chronic Constipation, CIC, Constipation Predominant Irritable Bowel Syndrome
What this study did
NCT05134584 · RenJi Hospital
2021-01-01 – 2022-02 · Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome
What this study did
NCT02837783 · Ironwood Pharmaceuticals, Inc.
2016-12-21 – 2018-10-31 · Irritable Bowel Syndrome Characterized by Constipation
What this study did
NCT02590432 · Forest Laboratories
2015-11-01 – 2018-02-05 · Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
What this study did
Other / comorbidity
NCT03119584 · Texas Tech University Health Sciences Center, El Paso
2015-09-01 – 2027-01 · Chronic Constipation, Diabete Mellitus
What this study did
NCT06748638 · Haifeng Lan
2024-09-01 – 2025-10-01 · Lactulose, Bowel Preparation
What this study did
NCT02465385 · University of Virginia
2015-02 – 2016-06 · Crohn's, Ulcerative Colitis, Gastrointestinal Bleeding
What this study did
NCT06989268 · Universitaire Ziekenhuizen KU Leuven
2014-02-10 – 2015-06-03 · Chronic Constipation
What this study did
Early phase / not applicable (8)
Irritable Bowel Syndrome with Constipation
NCT05796388 · Mayo Clinic
2024-05-31 – 2026-10 · Irritable Bowel Syndrome With Constipation
What this study did
NCT02078323 · Augusta University
2014-02 – 2018-07-20 · Irritable Bowel Syndrome With Constipation (IBS-C)
What this study did
Other / comorbidity
NCT07780344 · University of Nottingham
2026-09 – 2027-08 · Cystic Fibrosis (CF)
What this study did
NCT05291325 · Changhai Hospital
2022-05-25 – 2024-04-28 · Bowel Preparation for Colonoscopy
What this study did
NCT06091735 · Jinling Hospital, China
2023-08-01 – 2024-02-25 · Bowel Preparation
What this study did
NCT05379491 · Zhiguo Liu
2022-08-01 – 2023-07-15 · Colonoscopy
What this study did
NCT05137145 · Second Affiliated Hospital of Xi'an Jiaotong University
2021-09-01 – 2022-04-30 · Bowel Preparation
What this study did
NCT02239510 · TriHealth Inc.
2014-09 – 2016-06 · Chronic Idiopathic Constipation
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT04804267 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2021-03-05 – 2022-08-31 · Chronic Idiopathic Constipation
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02360384 · Wingate Institute of Neurogastroenterology
2015-11 – 2016-12 · Irritable Bowel Syndrome
What this study did

Competitive landscape

This drug's own stage for Irritable Bowel Syndrome with Constipation: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Linaclotide (Linzess): this drugApprovedPeptideGuanylate cyclase-C (GC-C)Weak signal
NCT03573908: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)): Placebo -1.182 score on a scale (Standard Error 0.109) | Linaclotide 290 µg -1.898 score on a scale (Standard Error 0.111)
Tenapanor (Ibsrela)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Reliable signalNo reviewed efficacy summary in this indication
Brenipatide
Phase 3(overall)
PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Linzess (linaclotide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8 …Active not recruiting
Est. primary completion 2026-11 · NCT03796884 · CT.gov ↗
What to watch
December 2026 (1)
Phase 4Irritable Bowel Syndrome with ConstipationNot yet recruiting
Est. primary completion 2026-12-31 · NCT07431957 · CT.gov ↗
What to watch
2027 (1)
May 2027 (1)
Early phase / not applicableCystic Fibrosis (CF)Not yet recruiting
Est. primary completion 2027-05 · NCT07780344 · CT.gov ↗
What to watch

See the full readout calendar ↗